Compare 8x8 Inc (EGHT) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs Merck & Co., Inc. — how do they compare? 8x8 Inc trades at $2.02 (market cap $309.09M), while Merck & Co., Inc. trades at $133.14 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 1041× 8x8 Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while 8x8 Inc pays none. Which is the better fit depends on your goals.
| EGHT | MRK | |
|---|---|---|
Market Cap | $309.09M | $321.77B |
Sector | Technology | Health |
52-Week High | $2.76 | $131.84 |
52-Week Low | $1.59 | $77.60 |
Enterprise Value | $576.02M | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.01, down 10.27% today, with a bullish technical signal from moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent news highlights AI platform expansion and partner program enhancements driving growth.
The outlook appears constructive with analyst consensus target of $3.13 representing 56% upside potential. Key risks include high debt levels and negative retained earnings, while catalysts include continued AI adoption and revenue growth acceleration toward profitability.
Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue reached $65.01B in 2025, and net income margin improved to 28.07%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, supported by analyst consensus favoring a buy rating (67.57%) and a price target of $140.36. Key opportunities include pipeline expansion through M&A and solid cash flow generation. Risks involve high valuation multiples, such as a P/E of 104.34, and potential integration challenges from acquisitions. Investors should weigh growth prospects against elevated earnings expectations and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
